Sermonix to Present Updated Data from ELAINE-2 Clinical Trial of Lasofoxifene in Combination with…
COLUMBUS, Ohio, May 31, 2022 (GLOBE NEWSWIRE) -- Sermonix Pharmaceuticals Inc., a privately held biopharmaceutical company developing innovative therapeutics to specifically treat ESR1-mutated metastatic breast and gynecological cancers,…